Here are relevant reports on : central-nervous-system-drug-delivery-market
-
Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implantable, Syrups, Gels, Pulmonary, Tablets, Syringes], Application (Cancer, Diabetes), Facility of Use (Hospital, Home Care) -Global Forecast to 2029
The global pharmaceutical drug delivery market, valued at US$1,831.1B in 2023, is forecasted to grow at a 5.5% CAGR, reaching US$1,949.4B by 2024 and US$2,546.0B by 2029. The increasing patient population with chronic diseases, coupled with the growing geriatric population, rising technological advancements in pharmaceutical drug delivery products offering enhanced patient convenience and compliance, the growing adoption of home-based and self-administration, rising government initiatives promoting accessibility to pharmaceutical drug delivery, and the increasing demand for biosimilars and biologics are likely to support market growth.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
-
Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application (Diagnostics (Clinical, PoC), Research (Proteomic, Genomics, Cell), Therapeutics (Drug Delivery, Wearables)), End User- Global Forecast to 2029
The global microfluidics market, valued at US$21.36B in 2023, is forecasted to grow at a 7.8% CAGR, reaching US$22.43B by 2024 and US$32.67B by 2029. The rising requirement of point-of-care diagnostics is an important factor, that helps to detect cancer, infectious diseases, and chronic illnesses, for which microfluidic devices are preferred due to their accuracy.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Gold Nanoparticles Market by Process (Physical, Chemical, Biological), Application (Imaging, Targeted Drug Delivery, Proton Therapy, In-Vitro Assays, Sensors, Probes, Catalysis), End-Use Industry and Region - Global Forecast to 2029
The gold nanoparticles market is expected to grow from USD 0.50 billion in 2024 to USD 1.11 billion in 2029, at a CAGR of 16.3% during the forecast period. Prominent companies include BBI Solutions (UK), Cytodiagnostics Inc (Canada), Fortis Life Sciences, LLC. (US), Meliorum Technologies, Inc (US), TANAKA PRECIOUS METAL GROUP Co., Ltd. (Japan), Merck KGaA (Germany), Nanopartz, Inc (US), CD Bioparticles (US), Nano Labs (India), Nanocs Inc. (US), NanoHybrids (US), Sona Nanotech (Canada), Sisco Research Laboratories Pvt, Ltd. (India), Nanoprobes, Inc (US), American Elements (US), TORSKAL (France), Abcam Limited (UK), Particular GmbH (Germany), Dongguan Sat Nano Technology Material Co., Ltd (China), Nano Flow (Belgium), Strem Catalog (US), Nanorh (India), SkySpring Nanomaterials (US), Aurion (Netherlands), NNCrystal US Corporation (US), and among others.
- Published: March 2025
- Price: $ 4950
- TOC Available:
-
Electronic Drug Delivery Systems Market by Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024
The electronic drug delivery system market is expected to grow from USD 7.8 billion in 2019 to USD 11.9 billion by 2024, at a compound annual growth rate (CAGR) of 8.7%. during the forecast period.The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US).
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
COVID-19 Impact on Medical Tubing Market by Material (PVC, TPE & TPU, Polyolefin, and Silicone), Application (Drug Delivery, Bulk Disposable Tubing, Catheters & Cannulas, and Special Applications) and Country - Forecast to 2021
The COVID-19 Impact on Medical Tubing Market is expected to grow from USD 2.6 billion in 2020 to USD 2.9 billion by 2021, at a CAGR of 13.2% during the forecast period. Zeus Industrial Products (US), Saint Gobain Performance Plastics (France), Teleflex (US), Optinova (US), and Lubrizol Corporation (Vesta) (US), among others, are the key players operating in the medical tubing market.
- Published: April 2020
- Price: $ 4950
- TOC Available:
-
Medical Device Contract Manufacturing Market by Device Type (IVD, Cardiovascular, Drug Delivery (Autoinjectors, Infusion Device), Diabetes Care, Orthopedic, Ophthalmology, Endoscopy, Surgical), Device Class (I, II, III), Services & Region - Global Forecast to 2029
The global medical device contract manufacturing market, valued at US$71.1B in 2023, is forecasted to grow at a 11.4% CAGR, reaching US$78.9B by 2024 and US$149.4B by 2029. The key factors which are driving the growth of this market includes, low labor costs, traditionally, CDMOs in certain regions, like China, offered significantly lower labor costs compared to developed nations. Increasing demand for medical devices used in geriatric care, increased affordability for medical procedures and devices are some of the factors driving the growth of the market.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Global Forecast to 2021
The global pulmonary drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis. Emerging markets such as India, China, & Japan and growth in online marketing channels are expected to offer lucrative growth opportunities for market players in the coming years. On the other hand, factors such as regulatory issues and pricing pressures are the major factors restraining market growth.
- Published: February 2017
- Price: $ 4950
- TOC Available:
-
Live Cell Encapsulation Market by Technique (Dripping (Simple, Electrostatic), Coaxial Airflow, Liquid Jet), Polymer (Alginate, Chitosan, Silica, Cellulose Sulfate), Application (Probiotics, Transplant, Drug Delivery, Research) - Forecast to 2024
The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2% during the forecast period. Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management. BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Global Albumin Market, by Product (Human Serum Albumin, Bovine Albumin, Recombinant Serum Albumin) by Application (Therapeutic, Drug Delivery, Culture Media, Vaccine Ingredient) by Region - Forecast to 2022
The global albumin market is projected to grow at a CAGR of around 6% during the forecast period (2017-2022). Factors such as the high demand of albumin in R&D activities, rising non-therapeutic application of albumin, development of plant based albumin, rising production of immunoglobulins, and rise in plasma collection are driving the market. However, the stringent regulations, limited reimbursement, and irrational uses and adverse effects associated with albumin are the factors restraining the growth of this market.
- Published: June 2025
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
